MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.68
+0.74
+2.65%
After Hours: 29.46 +0.78 +2.70% 19:47 03/05 EST
OPEN
28.10
PREV CLOSE
27.94
HIGH
28.76
LOW
26.18
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
73.49
52 WEEK LOW
24.24
MARKET CAP
1.93B
P/E (TTM)
-2.8828
1D
5D
1M
3M
1Y
5Y
bluebird bio Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (BLUE); Lead Plaintiff Deadline is April 13, 2021
Philadelphia, Pennsylvania--(Newsfile Corp. - March 5, 2021) - Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. ("bluebird" or the "Company") on behalf of investors who purchased bluebird securities (NASDAQ: BLU...
Newsfile · 2d ago
Global Thalassemia Market Outlook, Industry Analysis and Prospect 2020 -2026
Mar 04, 2021 (Heraldkeepers) -- COMTEX_382127326/2582/2021-03-04T06:58:46 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 3d ago
Anemia Drugs Market Size by Region 2021, Latest Trends, Key Players with Growth Rate, Total Revenues, Impact of COVID-19 on Global Industry and Recovery by 2027
The Express Wire · 3d ago
Alpha Thalassemia Market Set to Witness Growth 2021, Emerging industries, Challenges and Threats Faced by Key Vendors, Development Trends, Share, Size, Demand and 2026 Forecast Research Report
The Express Wire · 3d ago
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline BLUE
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020, inclusive (the “Class Period”) of the ...
GlobeNewswire · 3d ago
CAR T Cell Therapy Market 2021: Impact of COVID 19 on Industry Growth, Top Manufacture, Size, Regional Analysis and Forecast to 2026
Mar 03, 2021 (WiredRelease via Comtex) -- To be aware of the market in detail, the market research report is the perfect solution. Report such as Global CAR...
marketresearch.biz · 4d ago
Global Adrenoleukodystrophy Drugs Market Growth Analysis with Trends 2021: Business Insights of Leading Players, Research with Size, Key Challenges with Covid19 Impact, Opportunities Forecast to 2027
Mar 03, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Adrenoleukodystrophy Drugs Market”...
The Express Wire · 4d ago
DJ bluebird bio Price Target Cut to $45.00/Share From $50.00 by Morgan Stanley
Dow Jones · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLUE. Analyze the recent business situations of bluebird bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLUE stock price target is 46.53 with a high estimate of 86.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 487
Institutional Holdings: 64.51M
% Owned: 96.07%
Shares Outstanding: 67.14M
TypeInstitutionsShares
Increased
92
5.53M
New
101
-451.54K
Decreased
84
5.89M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Daniel Lynch
President/Chief Executive Officer/Director
Nick Leschly
Chief Financial Officer/Chief Accounting Officer
William Baird
Chief Operating Officer/Secretary
Jason Cole
Chief Scientific Officer
Philip Gregory
Other
David Davidson
Other
Alison Finger
Other
Joanne Smith-Farrell
Director
Ramy Ibrahim
Director
Denice Torres
Independent Director
John Agwunobi
Independent Director
Wendy Dixon
Independent Director
David Schenkein
Independent Director
William Sellers
Independent Director
Mark Vachon
No Data
About BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.